SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Q2 FY23 Earnings Concall Aug. 18, 2022 Corporate Participants: P. Vamsi Krishna -- Executed Director LakshminarayanaTammineedi -- Chief
Categories
Health Care
Apollo Hospitals research report at a glimpse
Stock Data: TickerAPOLLOHOSPExchangeBSE and NSE IndustryHealthcare Why is the stock price rising? Shares of Apollo Hospitals Enterprise Ltd have gained 8.84% over the
Apollo Hospitals Enterprise Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/niPJDB-NX_Y Key highlights from Apollo Hospitals Enterprise Limited (APOLLOHOSP) Q1 FY23 Earnings Concall Q&A Highlights: Nitin Gosar from Invesco asked about the
Divi’s Laboratories Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/EPaxfKgyoZQ Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Q&A Highlights: Tushar Manudhane from Motilal Oswal asked about the
Apollo Hospitals Enterprise Limited Q1FY23; 35% fall in Profits
Revenue for Q1 FY23 has increased by 1% YoY to ₹ 37,956 millions. Profits have fallen by 35% YoY to ₹ 31,711
Aurobindo Pharma Limited Q1FY23; 32% fall in Profits
Revenue for Q1 FY23 has increased by 9% YoY to ₹ 6,235.9 crores. Profits have fallen by 32% YoY to ₹ 520.5
Divi’s Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Transcript
Divi's Laboratories Ltd (NSE:DIVISLAB) Q1 FY23 Earnings Concall dated Aug. 12, 2022 Corporate Participants: Satish Choudhury -- Company Secretary and Chief Investor
Infographic: Divi’s Lab Q1 results out, Net profit rises 26%
On Friday, Pharmaceuticals company Divis Laboratories reported a 26% rise in its consolidated net profit at ₹702 crore as compared to ₹557
Hikal Limited (HIKAL) Q2 FY23 Earnings Concall Transcript
Hikal Limited (NSE:HIKAL) Q2 FY23 Earnings Concall dated Aug. 11, 2022 Corporate Participants: Sameer Hiremath -- Managing Director Manoj Mehrotra -- President-Pharmaceuticals Vimal
Zydus Lifesciences Ltd Q1FY23; Profit suffer with rise in expenses
Revenue for Q1 FY23 has increased by 1.8% YoY to ₹40,727 millions. Profits decreased by 12% YoY to ₹5,183 millions because Total
Glenmark Life Sciences Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/02Igs_HUAfo Key highlights from Glenmark Life Sciences Limited (GLS) Q1 FY23 Earnings Concall Q&A Highlights: [00:14:56] Neha Manpuria from Bank of America
Rainbow Children’s Medicare Ltd (RAINBOW) Q2 FY23 Earnings Concall Transcript
Rainbow Children's Medicare Ltd (NSE:RAINBOW) Q2 FY23 Earnings Concall dated Aug. 09, 2022 Corporate Participants: Siddharth Rangnekar -- Investor Relations Ramesh Kancharla
SUVEN PHARMACEUTICALS LTD (SUVEN) Q1 FY23 Earnings Concall Transcript
SUVEN PHARMACEUTICALS LTD (NSE: SUVEN) Q1 FY23 Earnings Concall dated Aug. 08, 2022 Corporate Participants: Rishab Barar -- Investor Relations Venkat Jasti -- Managing Director Analysts:
Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline
Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for
Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly
Torrent Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights
Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY23 Earnings Concall Management Update: TORNTPHARM launched four products in 1Q23 and will be
Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights
Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in
Piramal Enterprises Limited Q1FY23; 8% fall in Profits
Revenue for Q1 FY23 has increased by 22% YoY to ₹ 3,548 crores. Profits have fallen by 8% YoY to ₹ 496.09
Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Transcript
Sun Pharmaceutical Industries Ltd (NSE:SUNPHARMA) Q1 FY23 Earnings Concall dated Jul. 29, 2022 Corporate Participants: Nimish Desai -- Investor Relations Dilip Shanghvi
Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/gMXrmnAGz9Y Key highlights from Laurus Labs Limited (LAURUSLABS) Q1 FY23 Earnings Concall Management Update: LAURUSLABS said it expects the US filing pace
Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY22 Earnings Concall Transcript
Torrent Pharmaceuticals Ltd (NSE:TORNTPHARM) Q1 FY22 Earnings Concall dated Jul. 29, 2022 Corporate Participants: Sudhir Menon -- Executive Director, Finance and Chief